

DBRL/SEC/SE/23-24/15

April 22, 2023

To,  
**The Head-Listing & Compliance**  
**Metropolitan Stock Exchange of India Limited**  
Building A, Unit 205A, 2<sup>nd</sup> Floor,  
Piramal Agastya Corporate Park,  
L.B.S Road, Kurla West,  
Mumbai-400070

**The Listing Department**  
**The Calcutta Stock Exchange Ltd.**  
7, Lyons Range,  
Kolkata – 700 001

**Subject: Disclosure under Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time**

Dear Sir/Madam,

Pursuant to Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we wish to inform you that Dalmia Bharat Refractories Limited (**‘Company’**) has decided to acquire 2.34% of the post issued and paid-up share capital of Veeda Clinical Research Limited by subscribing to 13,61,582 equity shares of face value INR 02/- each at a price of INR 367.22 per share on private placement basis.

Further, it is also informed that the Board of Directors of the Company in their meeting held on April 21, 2023 have approved the appointment of Mr. Rahul Sahni as the Chief Financial Officer of the Company with immediate effect.

The detailed disclosure pursuant to SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015 is enclosed herewith as **Annexure I**.

Kindly take the above information on your records and oblige.

Thanking you,

Yours faithfully,  
For **Dalmia Bharat Refractories Limited**



**(Meghna Saini)**  
**Company Secretary**  
**Membership No. A42587**

**Encl.: as above**

**Dalmia Bharat Refractories Limited**

e snccil@dalmiarf.com w www.dalmiaocl.com CIN: L26100TN2006PLC061254

Regd. Office: Dalmiapuram - 621651, Distt. Tiruchirapalli, TN, India Corporate Office: 4, Scindia House, Connaught Place, New Delhi - 110001, India

Plants: Rajgangpur Distt. Sundergarh - 770017, OD; Dalmiapuram Distt. Tiruchirapalli - 621651, TN; **Khambhalia** P Box 10, Jam Khambhalia, Distt.

Devbhumi, Dwarka, GJ; **Bhilai** 1174/1 & 1174/2, Joratarai Industrial Area, P.O. Mangata Distt., Rajnandgaon - 491441, CG

Sales Office: Delhi 011 23457100, Kolkata 033 67012600, Bhubaneswar 0674 6773332 & Chennai 044 28301244

A **Dalmia Bharat Group** company

**ANNEXURE- I**

**A. Acquisition of equity shares of Veeda Clinical Research Limited**

S No.	Particulars	Details of transaction
1.	Name of the target entity, details in brief such as size, turnover etc.	The name of the target entity is Veeda Clinical Research Limited.  The net profit before tax and after tax for the FY 2021-2022 is INR 25,20,32,499 and INR 18,33,29,084 respectively.
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms length”	The acquisition does not fall within related party transaction(s) and the promoter/ promoter group/ group companies have no interest in the target entity.
3.	Industry to which the entity being acquired belongs	Other professional, scientific and technical activities
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Diversification of business
5.	Brief details of any governmental or regulatory approvals required for the acquisition	None
6.	Indicative time period for completion of the acquisition	Within 60 Days from the date of receipt of Share Application Money by target entity
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
8.	Cost of acquisition or the price at which the shares are acquired	INR 367.22 (Face Value INR 2 + Premium of INR 365.22)
9.	Percentage of shareholding / control acquired and / or number of shares acquired	The Company is acquiring 13,61,582 equity shares (2.34% of the post issued and paid-up share capital) of Veeda Clinical Research Limited having face value of INR. 2/- each at a price of INR 367.22 (Face Value INR 2 + Premium of INR 365.22)
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Products/ line of business of target company: Professional, scientific and technical activities  Date of incorporation: 23/04/2004  Last 3 years turnover:  FY 21-22: INR 2239.31 Million FY 20-21: INR 1958.14 Million

**Dalmia Bharat Refractories Limited**

e snccil@dalmiarf.com w www.dalmiaocl.com CIN: L26100TN2006PLC061254

Regd. Office: Dalmiapuram - 621651, Dist. Tiruchirapalli, TN, India Corporate Office: 4, Scindia House, Connaught Place, New Delhi - 110001, India

Plants: Rajgangpur Distt. Sundergarh - 770017, OD; Dalmiapuram Distt. Tiruchirapalli - 621651, TN; Khambhalia P Box 10, Jam Khambhalia, Distt.

Devbhumi, Dwarka, GJ; Bhilai 1174/1 & 1174/2, Joratarai Industrial Area, P.O. Mangata Distt., Rajnandgaon - 491441, CG

Sales Office: Delhi 011 23457100, Kolkata 033 67012600, Bhubaneswar 0674 6773332 & Chennai 044 28301244

A Dalmia Bharat Group company

		FY 19-20: 1512.73 Million  Country in which the entity in which stake is being acquired has presence and any other significant information: Global presence
--	--	---

**B. Appointment of Mr. Rahul Sahni as the Chief Financial Officer of the Company**

S No.	Particulars	Details
1.	Reason for Change viz., appointment, resignation, removal, death or otherwise	Appointment
2.	Date of appointment/cessation (as applicable) & term of appointment	April 21, 2023
3.	Brief Profile	Chartered Accountant with more than 13 years of experience in manufacturing industry with strong business development professional skills in Negotiation Treasury, Banking, Fund Raising, Project Financing, Working Capital, Credit rating etc.
4.	Disclosure of relationships between directors	None



**Dalmia Bharat Refractories Limited**

e snccil@dalmiarf.com w www.dalmiaocl.com CIN: L26100TN2006PLC061254

Regd. Office: Dalmiapuram - 621651, Distt. Tiruchirapalli, TN, India Corporate Office: 4, Scindia House, Connaught Place, New Delhi - 110001, India

Plants: Rajgangpur Distt. Sundergarh - 770017, OD; Dalmiapuram Distt. Tiruchirapalli - 621651, TN; Khambhalia P Box 10, Jam Khambhalia, Distt.

Devbhumi, Dwarka, GJ; Bhilai 1174/1 & 1174/2, Joratarai Industrial Area, P.O. Mangata Distt., Rajnandgaon - 491441, CG

Sales Office: Delhi 011 23457100, Kolkata 033 67012600, Bhubaneswar 0674 6773332 & Chennai 044 28301244

A Dalmia Bharat Group company